Showing results (21-30 of 32) with videos related to
Sort By:
Pageof 4
Blood|March 14, 2024
Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphomaJames K Godfrey, Lei Gao, Geoffrey Shouse, et al.JCI Insight|May 22, 2024
BET inhibition reforms the immune microenvironment and alleviates T cell dysfunction in chronic lymphocytic leukemiaAudrey L Smith, Sydney A Skupa, Alexandria P Eiken, et al.Journal of the National Comprehensive Cancer Network : JNCCN|September 2, 2020
Considerations for Use of Hematopoietic Growth Factors in Patients With Cancer Related to the COVID-19 PandemicElizabeth A Griffiths, Laura M Alwan, Kimo Bachiashvili, et al.Blood Advances|October 8, 2025
Polatuzumab vedotin in CNS lymphoma: proof-of-concept study for blood-brain barrier penetrationLei Gao, Avyakta Kallam, Geoffrey Shouse, et al.NEJM Evidence|February 6, 2024
Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid CancersMichael L Wang, Jacqueline C Barrientos, Richard R Furman, et al.Blood|March 3, 2026
Real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphomaJennifer L Crombie, Sairah Ahmed, Matthew J Frigault, et al.Journal of the National Comprehensive Cancer Network : JNCCN|January 8, 2020
NCCN Guidelines Insights: Hematopoietic Growth Factors, Version 1.2020Pamela Sue Becker, Elizabeth A Griffiths, Laura M Alwan, et al.Journal of the National Comprehensive Cancer Network : JNCCN|May 11, 2022
NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022Elizabeth A Griffiths, Vivek Roy, Laura Alwan, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2025
Cell-of-Origin Subtype Predicts Response to Polatuzumab Vedotin in Large B-cell LymphomaEdward R Scheffer Cliff, Guido D Pelaez, Fei Wan, et al.Journal of the National Comprehensive Cancer Network : JNCCN|March 11, 2022
T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in OncologySteven M Horwitz, Stephen Ansell, Weiyun Z Ai, et al.Pageof 4